Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Faes FarmaXMAD:FAE -2.32%95 3-Year Share Buyback Ratio is 0.70 as of Jun. 2026. GuruFocus rates XMAD:FAE with a GF Score™ of 95/100 and a GF Value™ of €5.52 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 646 Drug Manufacturers companies, Faes Farma ranks better than 89.63% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Faes Farma's current 3-Year Share Buyback Ratio was 0.70%.
The historical rank and industry rank for Faes Farma's 3-Year Share Buyback Ratio or its related term are showing as below:
XMAD:FAE'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -12.5 Med: -3.25 Max: 0.7
Current: 0.7
During the past 13 years, Faes Farma's highest 3-Year Share Buyback Ratio was 0.70%. The lowest was -12.50%. And the median was -3.25%.
XMAD:FAE's 3-Year Share Buyback Ratio is ranked better than 89.63% of 646
companies
in the Drug Manufacturers industry
Industry Median: -2.1
vs XMAD:FAE: 0.70
Faes Farma (XMAD:FAE) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Faes Farma 3-Year Share Buyback Ratio Related Terms
XMAD:FAE vs ZTS, UTHR, VTRS: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faes Farma 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Faes Farma's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Faes Farma's 3-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.70 mean?
Faes Farma (XMAD:FAE) has a 3-Year Share Buyback Ratio of 0.70 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Faes Farma and its competitors. According to the industry distribution chart, Faes Farma ranks #67 out of 646 companies in the Drug Manufacturers industry, placing it in the top 10.4%.
Is Faes Farma's 3-Year Share Buyback Ratio too high?
Faes Farma's current 3-Year Share Buyback Ratio is 0.70. Based on the distribution chart, Faes Farma ranks #67 out of 646 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Faes Farma has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Faes Farma's 3-Year Share Buyback Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Faes Farma ranks #67 out of 646 companies for 3-Year Share Buyback Ratio. This places Faes Farma in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Faes Farma and its competitors. Faes Farma's current 3-Year Share Buyback Ratio is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faes Farma stock overvalued right now?
Based on GuruFocus' analysis, Faes Farma (XMAD:FAE) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.52, compared to a current price of €4.43 — trading 19.7% below its estimated fair value. The current 3-Year Share Buyback Ratio is 0.70. Faes Farma's overall GF Score™ is 95/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Faes Farma (XMAD:FAE), the current 3-Year Share Buyback Ratio is 0.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Faes Farma (XMAD:FAE) Overvalued in 2026?
Based on GuruFocus' analysis, Faes Farma stock appears to be undervalued.
The current stock price of €4.43 is trading 19.7% below its estimated GF Value™ of €5.52.
GuruFocus considers Faes Farma to be Modestly Undervalued.
Key valuation signals for XMAD:FAE:
3-Year Share Buyback Ratio: 0.70
GF Value™: €5.52 vs. price of €4.43 (19.7% below fair value)
No single metric tells the full story. See the XMAD:FAE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.
95GF Score
Get the complete analysis for XMAD:FAE
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:FAE has been successfully added to your 
